About lineage cell therapeutics - LCTX
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
LCTX At a Glance
Lineage Cell Therapeutics, Inc.
2173 Salk Avenue
Carlsbad, California 92008-7354
| Phone | 1-442-287-8990 | Revenue | 14.56M | |
| Industry | Biotechnology | Net Income | -63,533,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 53.237% | |
| Fiscal Year-end | 12 / 2026 | Employees | 77 | |
| View SEC Filings |
LCTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 26.401 |
| Price to Book Ratio | 9.114 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -15.642 |
| Enterprise Value to Sales | 22.652 |
| Total Debt to Enterprise Value | 0.007 |
LCTX Efficiency
| Revenue/Employee | 189,038.961 |
| Income Per Employee | -825,103.896 |
| Receivables Turnover | 9.319 |
| Total Asset Turnover | 0.129 |
LCTX Liquidity
| Current Ratio | 5.204 |
| Quick Ratio | 5.204 |
| Cash Ratio | 4.907 |
LCTX Profitability
| Gross Margin | 94.195 |
| Operating Margin | -149.622 |
| Pretax Margin | -471.606 |
| Net Margin | -436.473 |
| Return on Assets | -56.273 |
| Return on Equity | -103.365 |
| Return on Total Capital | -135.269 |
| Return on Invested Capital | -100.96 |
LCTX Capital Structure
| Total Debt to Total Equity | 5.43 |
| Total Debt to Total Capital | 5.15 |
| Total Debt to Total Assets | 2.149 |
| Long-Term Debt to Equity | 3.515 |
| Long-Term Debt to Total Capital | 3.334 |